Ardevora Asset Management LLP Sells 4,700 Shares of Abcam plc (NASDAQ:ABCM)

Ardevora Asset Management LLP trimmed its position in Abcam plc (NASDAQ:ABCM) by 27.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,736 shares of the company’s stock after selling 4,700 shares during the quarter. Ardevora Asset Management LLP’s holdings in Abcam were worth $312,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ABCM. ProShare Advisors LLC acquired a new stake in Abcam during the 1st quarter valued at $200,000. New York State Common Retirement Fund raised its position in shares of Abcam by 71.1% in the first quarter. New York State Common Retirement Fund now owns 13,258 shares of the company’s stock valued at $178,000 after purchasing an additional 5,510 shares during the period. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Abcam during the 1st quarter worth about $919,000. State Street Corp bought a new stake in shares of Abcam during the 1st quarter worth about $2,990,000. Finally, Geode Capital Management LLC grew its stake in Abcam by 734.8% in the 1st quarter. Geode Capital Management LLC now owns 106,049 shares of the company’s stock valued at $1,427,000 after buying an additional 93,346 shares during the last quarter. 90.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. William Blair downgraded shares of Abcam from an “outperform” rating to a “market perform” rating in a research report on Monday, August 28th. Royal Bank of Canada reissued a “sector perform” rating on shares of Abcam in a report on Tuesday, August 22nd. SVB Leerink lowered Abcam from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 29th. SVB Securities downgraded Abcam from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 29th. Finally, Bank of America upgraded shares of Abcam from a “neutral” rating to a “buy” rating in a research note on Friday, June 16th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $23.00.

Abcam Trading Down 0.2 %

Shares of ABCM stock opened at $22.74 on Friday. Abcam plc has a 1 year low of $12.48 and a 1 year high of $25.32. The stock has a 50 day simple moving average of $23.00 and a 200 day simple moving average of $18.89.

About Abcam

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools.